Alterity Therapeutics Limited (PBN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alterity Therapeutics Limited (PBN) has a cash flow conversion efficiency ratio of -0.222x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-5.06 Million ≈ $-5.91 Million USD) by net assets (€22.81 Million ≈ $26.67 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PBN stock market capitalisation for the company's overall valuation and market capitalisation.
Alterity Therapeutics Limited - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Alterity Therapeutics Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Alterity Therapeutics Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alterity Therapeutics Limited ranked by their cash flow conversion efficiency. See PBN operating cash flow to total debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Done.ai Group AB
ST:DONE
|
-0.014x |
|
Nordisk Bergteknik AB Series B
ST:NORB-B
|
-0.004x |
|
Gedeon Richter PLC
LSE:0QFP
|
0.038x |
|
Malee Group Public Company Limited
BK:MALEE
|
0.047x |
|
Futebol Clube do Porto - Futebol S.A.D.
LS:FCP
|
-0.266x |
|
SensorView Co Ltd
KQ:321370
|
-0.080x |
|
Cauldron Energy Ltd
AU:CXU
|
-0.606x |
|
Yatra Online Inc
NASDAQ:YTRA
|
-0.051x |
Annual Cash Flow Conversion Efficiency for Alterity Therapeutics Limited (2014–2025)
The table below shows the annual cash flow conversion efficiency of Alterity Therapeutics Limited from 2014 to 2025. View latest Alterity Therapeutics Limited stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | €42.40 Million ≈ $49.57 Million |
€-11.45 Million ≈ $-13.39 Million |
-0.270x | +70.44% |
| 2024-06-30 | €13.80 Million ≈ $16.13 Million |
€-12.61 Million ≈ $-14.74 Million |
-0.914x | -4.02% |
| 2023-06-30 | €22.81 Million ≈ $26.67 Million |
€-20.04 Million ≈ $-23.42 Million |
-0.878x | -152.49% |
| 2022-06-30 | €35.47 Million ≈ $41.47 Million |
€-12.34 Million ≈ $-14.42 Million |
-0.348x | +38.84% |
| 2021-06-30 | €30.47 Million ≈ $35.62 Million |
€-17.33 Million ≈ $-20.26 Million |
-0.569x | +56.88% |
| 2020-06-30 | €7.15 Million ≈ $8.36 Million |
€-9.43 Million ≈ $-11.03 Million |
-1.319x | -56.46% |
| 2019-06-30 | €16.55 Million ≈ $19.35 Million |
€-13.95 Million ≈ $-16.31 Million |
-0.843x | -117.06% |
| 2018-06-30 | €16.08 Million ≈ $18.80 Million |
€-6.25 Million ≈ $-7.30 Million |
-0.388x | -56.86% |
| 2017-06-30 | €23.69 Million ≈ $27.70 Million |
€-5.87 Million ≈ $-6.86 Million |
-0.248x | -4.68% |
| 2016-06-30 | €31.37 Million ≈ $36.67 Million |
€-7.42 Million ≈ $-8.67 Million |
-0.237x | +14.91% |
| 2015-06-30 | €39.11 Million ≈ $45.73 Million |
€-10.87 Million ≈ $-12.71 Million |
-0.278x | +22.62% |
| 2014-06-30 | €37.69 Million ≈ $44.06 Million |
€-13.54 Million ≈ $-15.83 Million |
-0.359x | -- |
About Alterity Therapeutics Limited
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II… Read more